Creatine Deficiency Disorders and Epilepsy

Creatine deficiency disorders are a group of inherited metabolic disorders in which the brain has too little creatine because creatine cannot be synthesised normally or cannot be transported into brain cells effectively. The group includes GAMT deficiency, AGAT deficiency and creatine transporter deficiency.

Developmental delay, cognitive impairment and speech-language difficulties are common across the group. Epilepsy is particularly important in GAMT deficiency and creatine transporter deficiency, although seizure frequency and severity vary widely.

Why creatine matters to the brain

Creatine forms part of the creatine-phosphocreatine system, which helps cells store and rapidly transfer high-energy phosphate. This system acts as an energy buffer in tissues with high and fluctuating energy demands, including brain and muscle.

If the brain cannot make or import enough creatine, energy handling becomes less efficient and neurological development and function can be affected.

The three primary creatine deficiency disorders

GAMT deficiency

Guanidinoacetate methyltransferase deficiency is caused by biallelic pathogenic variants in GAMT. Creatine production is impaired and guanidinoacetate accumulates.

GeneReviews reports that most affected people have developmental delay and cognitive impairment, while epilepsy and behavioural difficulties are also common. Movement disorders can occur in a substantial minority.

AGAT deficiency

L-arginine:glycine amidinotransferase deficiency is caused by biallelic pathogenic variants in GATM. This blocks an earlier step in creatine synthesis.

Developmental and speech-language difficulties are typical. Seizures have been reported but appear less prominent than in GAMT deficiency.

Creatine transporter deficiency

Creatine transporter deficiency is caused by pathogenic variants in SLC6A8. Creatine may be produced in the body, but transport into certain tissues — especially the brain — is impaired.

The disorder is X-linked and primarily affects males, although heterozygous females can also have neurological or cognitive symptoms.

Epilepsy in creatine deficiency disorders

Epilepsy is common in GAMT deficiency and creatine transporter deficiency. There is no single characteristic seizure type, and affected people may have focal or generalised seizure types depending on the disorder and individual.

Standard antiseizure medicines are used according to seizure type. GeneReviews notes that no single antiseizure medicine has been proven uniquely effective for creatine deficiency disorders.

Development and speech

Developmental delay and cognitive dysfunction are central features of all three disorders. Speech and language impairment can be particularly prominent and may be one of the clues that leads to metabolic investigation.

Behavioural features can include hyperactivity, autistic traits or self-injurious behaviour, especially in GAMT and creatine transporter deficiency.

Movement disorders

GAMT deficiency can cause dystonia, chorea or other abnormal movements. Movement disorders are less prominent in AGAT and creatine transporter deficiency but can still occur depending on the individual.

Movement symptoms can coexist with epilepsy and should not automatically be assumed to be seizure activity.

How the disorders are detected

Biochemical testing uses patterns of creatine, creatinine and guanidinoacetate in urine and plasma. The pattern differs between GAMT, AGAT and creatine transporter deficiency.

For example, GAMT deficiency typically causes elevated guanidinoacetate with low creatine, while AGAT deficiency causes low guanidinoacetate and low creatine. Creatine transporter deficiency often produces an increased urine creatine-to-creatinine ratio in affected males.

Brain magnetic resonance spectroscopy

Proton magnetic resonance spectroscopy — often written as ¹H-MRS — can demonstrate reduced or absent cerebral creatine.

This is a specialised MRI-based technique that measures brain metabolites rather than simply showing anatomy. A low creatine peak can provide an important clue but needs to be interpreted alongside biochemical and genetic testing.

Genetic testing

Diagnosis is confirmed by identifying pathogenic variants in the relevant gene: GAMT, GATM or SLC6A8.

Genomic testing may use a targeted metabolic or neurodevelopmental panel, exome sequencing or genome sequencing depending on the health system and clinical presentation.

Why early diagnosis matters

GAMT and AGAT deficiency are particularly important because treatment can restore cerebral creatine and improve neurological outcome, especially when started early.

GeneReviews notes that children diagnosed and treated from the newborn period or early infancy can have much better developmental outcomes than people diagnosed only after years of symptoms.

Treatment of GAMT deficiency

Treatment usually includes oral creatine supplementation to replace the missing end product.

Because guanidinoacetate accumulation may itself be neurotoxic, treatment can also include strategies to reduce its production, such as dietary arginine restriction and/or ornithine supplementation under specialist metabolic supervision.

The exact treatment plan varies by centre and individual.

Treatment of AGAT deficiency

AGAT deficiency is treated with creatine supplementation. Because guanidinoacetate is not accumulating, treatment is generally simpler than in GAMT deficiency.

Early treatment may substantially improve development and can prevent some manifestations when started before significant neurological injury has occurred.

Treatment of creatine transporter deficiency

Creatine transporter deficiency is more difficult to treat because the fundamental problem is transport of creatine into the brain.

Creatine supplementation alone often has limited effect. Some centres use combinations of creatine, arginine and glycine in an attempt to increase endogenous brain creatine synthesis, but response is variable and there is no universally effective disease-modifying treatment.

Why treatment does not replace epilepsy care

Even when metabolic treatment improves the underlying biochemical disorder, some people continue to have epilepsy and require conventional antiseizure medicines.

Metabolic treatment and epilepsy treatment therefore work alongside each other rather than being alternatives.

Monitoring treatment

Follow-up can include developmental assessment, seizure review, behavioural and movement assessment, brain MR spectroscopy and biochemical monitoring.

GeneReviews recommends monitoring kidney function during creatine supplementation because high-dose long-term creatine therapy can place additional demands on renal handling.

Newborn screening

GAMT deficiency has attracted particular interest for newborn screening because presymptomatic treatment may prevent severe developmental disability and epilepsy.

Newborn screening availability is country-specific. Some jurisdictions have introduced GAMT deficiency into screening programmes, while many countries do not currently include it.

This is an example of why a worldwide epilepsy resource should distinguish biological evidence from local screening policy.

Inheritance

GAMT and AGAT deficiency are autosomal-recessive. Creatine transporter deficiency is X-linked.

Inheritance pattern affects family recurrence risk and testing. Genetic counselling is therefore an important part of care after diagnosis.

Creatine deficiency is not the same as dietary creatine deficiency

These disorders are genetic defects in creatine synthesis or transport. They are not caused by eating too little dietary creatine.

Sports supplements and ordinary over-the-counter creatine products should not be used as a substitute for specialist metabolic treatment, particularly in children.

Worldwide access

Diagnosis depends on access to metabolic testing, genetic testing and, in some cases, MR spectroscopy. These services are concentrated in specialist centres and are not equally available worldwide.

Even where creatine itself is relatively inexpensive, long-term treatment of GAMT deficiency may require specialised dietary management, amino-acid supplementation and repeated biochemical monitoring that can be difficult to access.

The central point

Creatine deficiency disorders are not one condition and not every form has the same epilepsy risk or treatment response. GAMT and AGAT deficiency are especially important because early metabolic treatment can substantially change outcome, while creatine transporter deficiency remains more difficult to treat.

Sources

Medical note: treatment doses of creatine, ornithine, arginine restriction and other metabolic therapies require specialist supervision. They should not be started as self-treatment for unexplained seizures or developmental difficulties.

Evidence checked: September 2026.